After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more programs in development and greater industry prioritization than ever before, ...
An antibody-drug conjugate (ADC) that GSK licensed from China's Hansoh Pharma in a $1.7 billion deal last year has been given breakthrough status by the FDA. The coveted designation for GSK5764227 ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback